NAV
$39.15
AUM
$35.0M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.49
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +18.84% | +10.45% | +15.15% | +50.70% | +16.15% | +9.88% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 7.82% |
| 2 | MRK | Merck & Co Inc | 7.13% |
| 3 | ABBV | AbbVie Inc | 6.98% |
| 4 | BMY | Bristol-Myers Squibb Co | 6.82% |
| 5 | JNJ | Johnson & Johnson | 6.75% |
| 6 | VTRS | Viatris Inc | 4.05% |
| 7 | BIIB | Biogen Inc | 3.80% |
| 8 | PFE | Pfizer Inc | 3.52% |
| 9 | GILD | Gilead Sciences Inc | 3.36% |
| 10 | VRTX | Vertex Pharmaceuticals Inc | 3.35% |
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.
Inception Date: 2016-09-20